[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Capitol Health Call
December 9, 2009

Eye Drug Reversal

JAMA. 2009;302(22):2423. doi:10.1001/jama.2009.1804

The Centers for Medicare & Medicaid Services (CMS) reversed a payment coding decision that would have greatly enticed physicians to prescribe a very expensive medication, ranibizumab (Lucentis), to treat wet macular degeneration instead of a far more affordable drug, bevacizumab (Avastin), a development praised by Sen Herb Kohl (D, Wis), chairman of the Senate Special Committee on Aging. Both drugs are manufactured by Genentech Inc.

“I’m pleased that CMS heeded the concerns of the medical eye care community and the Aging Committee,” said Kohl in an October 28 statement.

First Page Preview View Large
First page PDF preview
First page PDF preview
×